Phio Pharmaceuticals Corp. financial data

Symbol
PHIO on Nasdaq
Location
King Of Prussia, PA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 05 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 824% % 80%
Debt-to-equity 10% %
Return On Equity -67% % 56%
Return On Assets -60% % 50%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11,617,250 shares 143%
Common Stock, Shares, Outstanding 11,617,250 shares 570%
Entity Public Float $11,200,000 USD 250%
Common Stock, Value, Issued $1,000 USD
Weighted Average Number of Shares Outstanding, Basic 5,984,017 shares 660%
Weighted Average Number of Shares Outstanding, Diluted 4,794,857 shares 840%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $4,618,000 USD 27%
General and Administrative Expense $4,602,000 USD 23%
Operating Income (Loss) $9,220,000 USD -25%
Nonoperating Income (Expense) $143,000 USD 110%
Net Income (Loss) Attributable to Parent $8,698,000 USD -22%
Earnings Per Share, Basic -1.45 USD/shares 84%
Earnings Per Share, Diluted -5.85 USD/shares 83%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $21,031,000 USD 291%
Assets, Current $21,476,000 USD 274%
Property, Plant and Equipment, Net $11,000 USD 450%
Operating Lease, Right-of-Use Asset $0 USD -100%
Other Assets, Noncurrent $0 USD -100%
Assets $21,487,000 USD 274%
Accounts Payable, Current $435,000 USD 72%
Employee-related Liabilities, Current $31,000 USD -86%
Accrued Liabilities, Current $905,000 USD 19%
Liabilities, Current $1,206,000 USD -21%
Operating Lease, Liability, Noncurrent $0 USD
Liabilities $1,340,000 USD 32%
Retained Earnings (Accumulated Deficit) $155,054,000 USD -5.9%
Stockholders' Equity Attributable to Parent $20,147,000 USD 327%
Liabilities and Equity $21,487,000 USD 274%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,275,000 USD 37%
Net Cash Provided by (Used in) Financing Activities $9,173,000 USD
Net Cash Provided by (Used in) Investing Activities $2,000 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 11,617,250 shares 570%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,775,000 USD 129%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD -100%
Deferred Tax Assets, Valuation Allowance $2,613,000 USD 675%
Deferred Tax Assets, Gross $2,630,000 USD 651%
Operating Lease, Liability $0 USD -100%
Payments to Acquire Property, Plant, and Equipment $2,000 USD
Property, Plant and Equipment, Gross $239,000 USD -22%
Operating Lease, Liability, Current $0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -100%
Deferred Tax Assets, Operating Loss Carryforwards $1,986,000 USD 7538%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $0 USD -100%
Additional Paid in Capital $175,200,000 USD 16%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $0 USD -100%
Share-based Payment Arrangement, Expense $113,000 USD 117%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%